Samsung leads in U.S. patents as overall grants hit four-year low
Self-driving vehicles, fossil fuel drilling and AI among hottest areas for R&D activity; applications hit an all-time high, according to annual analysis by IFI CLAIMS Patent Services
Reports and ProceedingsIMAGE: HIGHLIGHTS FROM THE IFI CLAIMS 2022 PATENT RANKING AND TRENDS ANALYSIS. view more
CREDIT: DIGITAL SCIENCE / IFI CLAIMS.
U.S. patent grants issued in 2022 dropped to their lowest level since 2018, and South Korean electronics titan Samsung took the top spot from longtime leader IBM as East made gains on West among the Top 50 patent assignees during the past year. Nonetheless, patent applications hit an all-time high in 2022 as the United States emerged from the COVID-19 pandemic – a harbinger for a resurgence in innovation and grants over the next one to two years.
These are among the findings by IFI CLAIMS Patent Services, a Digital Science company which compiles and tracks data from the U.S. Patent and Trademark Office (USPTO) and other patent-issuing agencies around the globe. The data can be found in the newly published 2022 U.S. Top 50 and IFI Global 250 patent rankings.
Highlights - patent ranking an [VIDEO] | EurekAlert! Science News Releases
Samsung takes the lead from IBM
Samsung came in atop the annual IFI Top 50 patent earners with longtime leader IBM in second place. This is the first time a company other than IBM has been in the top slot since 1993. Based on the data, IBM’s U.S. patent grants decreased in 2022, going from 8,681 in 2021 to 4,398 last year, a nearly 50 percent regression. But even Samsung, with 6,248 grants, saw a moderate decline (2 percent) from the prior year.
Still with one of the strongest U.S. patent portfolios, IBM’s new placement on this year’s list is attributable, according to IBM’s blog, to its heightened focus since 2020 on prioritizing open source, collaboration and partnerships, and advancing the state of the art around the company’s key technology areas including hybrid cloud, AI, quantum computing, semiconductors and security.
Following Samsung and IBM, the top 10 patent earners were Taiwan Semiconductor, Huawei Technologies, Canon, LG Electronics, Qualcomm, Intel, Apple and Toyota Motor.
The past year marks the third straight to see declines in patent grants, since the start of the pandemic. Across the board, U.S. patent grants declined just over 1 percent from 2021, representing a vigorous rebound following a 7 percent dip the prior year. Grants dropped from 327,321 to 323,015. Published patent applications, meanwhile, hurtled from 410,092 in 2021 to a record 417,922 last year, a 2 percent increase and the continuation of a five-year run of rising USPTO requests. Highlights from the full analysis and an overview of trends appear on the IFI website.
“Everything was trending upward until COVID hit, but grants have been declining. This might be due to the fact the USPTO faces a growing backlog of applications, some 700,000 currently, up from 540,000 unexamined patents in 2018,” said Mike Baycroft, CEO of IFI CLAIMS Patent Services. “But the continued growth in applications is encouraging for innovation. First comes the filing, then typically 12-18 months later the application becomes public, then in another 18 months the grant is issued, so we expect to see a post-COVID upturn in the next couple of years.”
A West-to-East shift in the Top 50
Looking at the Top 50 alone, IFI’s data noted a shift from West to East. In addition to Samsung’s ascendance, Asian-based companies on the list earned 14 percent more patents than Western countries in 2022 (41,055 vs. 35,365), far eclipsing Asia’s edge in 2021 of just 1 percent. Japan, China and South Korea alone accounted for 40,114 patents, compared to 32,130 for United States companies.
A total of three Chinese companies made the Top 50: Huawei at #4, BOE Technology Corp. at #11, and Guangdong Oppo sliding into the #43 spot, formerly occupied by its national counterpart Advanced New Technologies, which fell off the list in 2022.
U.S. awards majority of patents outside America
A stunning 56 percent of U.S. grants in 2022 did not go to U.S. firms. American companies, however, led among patent grantees, earning 142,703 patents, or 44 percent of all patents issued by the USPTO (vs. 46 percent in 2021) and more than three times as many as its closest national competitor, Japan (46,504). Chinese firms were third, with 24,538 grants during the last 12 months. South Korea (22,359) and Germany (14,746) rounded out the top five countries represented. Of the five countries to see an uptick in patent grants in the past year, China was the only one with double-digit growth, standing head and shoulders above the rest with almost 19 percent more than in 2021.
U.S. stalwarts lose position
Among U.S. companies, GE (-11), Texas Instruments (-7), AT&T (-9), Boeing (-8), Ford (-4), Microsoft (-6), Intel (-2), and Apple (-2) fell lower on the Top 50 list, while Dell (+18), and Hewlett-Packard Development Co. (+12) gained considerably in the rankings. Applied Materials and Capital One both entered the top 50 at #44 and #45, respectively. Amazon and Halliburton Energy Services were the only American companies that held their positions from the prior year, with Amazon earning 1,863, down 4 percent, and Halliburton earning 906, up 4 percent. The biggest non-American risers in the Top 50 were Japan’s Murata Manufacturing Company (#38) and Brother Industries (#49), which both leaped 10 spots from 2021.
Autonomous vehicle tech is hot; earth drilling keeps rocking
Technology related to autonomous vehicles (e.g., self-driving cars) ascended to the No. 1 spot among IFI’s Fastest Growing Technologies list last year, despite failing to crack the top 10 classes the year before. “Drive Control Systems for Autonomous Road Vehicles” saw a Compound Annual Growth Rate (CAGR) of 64.3 percent for the period 2018-2022. Of note is that while “Computing Based on Biological Models” dropped to No. 4 from its perch at No. 1 last year, Artificial Intelligence research has pervaded multiple patent categories, including Earth Drilling, “Quantum Computers” and “Machine Learning.”
Rounding out the top Fastest Growing Technologies were “Electrical Digital Data Processing” (CAGR 33.9%); “Special Features Related to Earth Drilling Including AI and Simulation Models” (CAGR 32.5%); “Computing Based on Biological Models” (CAGR 32.1%); and “Electrically Operated Smoking Devices” (CAGR 31.3%). Interestingly, “Cigars, Cigarettes” also made the Top 10 (CAGR 28.3%). Who would have thought in 2022 that patents for Earth Drilling and Cigars/Cigarettes would be among the fastest growing categories?
IFI noted that “Special Features Related to Earth Drilling,” which focuses on helping improve earth drilling for oil and gas had moved up from 6th in 2021 to 3rd in 2022. This led IFI to look at U.S. grants for “Green” patents which appear to outpace Earth Drilling by more than 2 to 1. Upon closer inspection IFI found that the majority of grants (66%) in the Green class are for mitigating technologies needed to battle effects of fossil fuels. Only about one-third of Green patents are for truly renewable energies (solar, wind, green hydrogen, water, etc.) where 2022 data show that Earth Drilling grants actually outpaced them by 27 percent.
“As far as patent activity is concerned, we’re not yet seeing a shift toward renewable energy, and some of the fast growing sub-technology areas are focused on improving and more efficiently harvesting traditional fossil fuel sources,” said Baycroft.
To view the full report, visit the 2022 Top 10 Fastest Growing Technologies.
Japan and Panasonic dominate total global patent holdings
As of January 3, 2023, Japanese companies owned more than one in three of all worldwide patent “families,” with 1.5 million or 40 percent of the Global 250. China is second with 25 percent and the U.S. is third with 16 percent. Panasonic leads the IFI Global 250 list with 94,341 patent families, and Samsung was just behind. Hitachi, Chinese Academy of Sciences and Canon rounded out the top five.
A patent family is a collection of global patent filings related to a single invention. As a result, a patent for the same invention filed in multiple jurisdictions is only counted once. The IFI Global 250 list is a look back at total active patent families owned by a single company, not just patents earned in any given year.
Japan also had 92 representative companies (37%) on the Global 250, well ahead of the U.S. (55 companies; 22%) and China (45 companies; 18%). Germany, France and South Korea had far fewer representative companies in the third, fourth and fifth positions.
IBM was the highest-ranking American company on this list, coming in at No. 16 with 43,014 patent families. Other U.S. concerns on this list included Microsoft (30th; 31,563 families), GE (38th; 27,008), Intel (44th; 23,758), Alphabet/Google (46th; 22,935) and Amazon (76th; 13,519).
Patent activity provides valuable insight into companies’ R&D activity for researchers, analysts, and investors. It speaks to productivity and IP strategy, and frequently reveals technology trends and the competitive landscape within various industries. Often the true value of a company lies with its intellectual properties, so examining patent assets is a key tool in gauging the intangible assets of publicly traded companies.
To create your own analysis, visit the IFI CLAIMS Live 1000, a free tool which uses data from the top 1000 companies that received patents across multiple countries and patent jurisdictions. The tool shows live data and offers interactive features that allow users to create and sort their own lists using a variety of filters.
About IFI CLAIMS Patent Services
IFI CLAIMS Patent Services uses proprietary data architecture to produce the industry’s most accurate patent database. The CLAIMS Direct platform allows for the easy integration of applications, other data sets, and analysis software. Headquartered in New Haven, Connecticut, with a satellite office in Barcelona, Spain, IFI CLAIMS is part of Digital Science, a digital research technology company based in London. For more information, visit www.ificlaims.com.
About Digital Science
Digital Science is a technology company working to make research more efficient. We invest in, nurture and support innovative businesses and technologies that make all parts of the research process more open and effective. Our portfolio includes admired brands including Altmetric, Dimensions, Figshare, ReadCube, Symplectic, IFI CLAIMS, Overleaf, Ripeta and Writefull. We believe that together, we can help researchers make a difference. Visit www.digital-science.com and follow @digitalsci on Twitter.
General Biomics and The Jackson Laboratory announce intellectual property licensing agreement
The agreement will aid in the understanding of the microbiome in human disease
Business AnnouncementFarmington, CONN. – General Biomics, Inc. and The Jackson Laboratory (JAX) announced an expansive and exclusive intellectual property licensing agreement across six areas of human health. The agreement will enable JAX to transfer hundreds of microbiome samples, as well as other materials, datasets and related know-how, accrued by researcher George Weinstock, Ph.D., formerly the director of microbial genomics and professor and Evnin Family Chair at The Jackson Laboratory for Genomic Medicine and professor of genetics and genome science at UConn Heath, to General Biomics. As part of this transaction, JAX will become a shareholder in General Biomics.
General Biomics, located in the UConn Technology Incubator in Farmington, was founded in 2020 by Dr. Weinstock and Dr. Yanjiao Zhou, an assistant professor at UConn Health researching human disease through the microbiome. General Biomics’ mission is to deliver novel multi-omic solutions to human healthcare through knowledge of the human microbiome. “The microbiome is a crucial key in our understanding of human disease. General Biomics is pleased to be able to utilize the materials and data we have collected and generated over many years at The Jackson Laboratory to assess and treat a variety of conditions,” said Weinstock, who will serve as executive vice president and chief scientific officer of the startup. “By obtaining these valuable materials and IP, we will be able to translate years of scientific research into therapies that could change lives for many individuals living with chronic conditions.”
During his career at JAX, Dr. Weinstock investigated the human microbiome in a wide variety of contexts, including how it contributes to human conditions and diseases such as aging, asthma, the immune response, cancer, substance use disorders, metabolic syndromes, and much more. He was named Evnin Family Chair at JAX in 2015. Before joining JAX, he served as associate director of The Genome Institute at Washington University in St. Louis, where he led the NIH effort to sequence the Human Microbiome. Previously, Dr. Weinstock was co-director of the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine in Houston, Texas, and professor of molecular and human genetics.
“At JAX, we take very seriously our role helping to translate research into therapeutics and providing hope to families dealing with devastating medical conditions,” said Lon Cardon, Ph.D., FMedSci, JAX president and CEO. “We are pleased to collaborate with General Biomics to support its mission to use the microbiome as a key predictor of and solution to a variety of conditions and diseases as well as the biomedical research sector’s growth in the State of Connecticut.”
In its initial product development program, supported by samples, materials and data licensed from JAX, General Biomics will address medical disorders that affect newborns and young infants, especially premature infants who require hospitalization. Dr. Weinstock and Dr. Zhou have found considerable evidence exists that the gut microbiome plays an important role in the development of these maladies. A key component of the program will collaborate with a large childrens’ hospital, the details of which will be announced in an upcoming news release from General Biomics. The intention of the program is to develop novel, patentable tests, which will greatly reduce the costs of hospitalization and dramatically reduce the mortality and morbidity in these patients. Other areas of health and disease that are contained in the agreement include: asthma, oncology, immune and inflammatory responses, aging, and health and wellness.
General Biomics received seed financing in January 2022, which has been used to begin its scientific operations and create its business strategy. Steve Lombardi, a genomics industry leader with over forty years of experience, is the company’s executive chairman and is leading its business efforts and fundraising activities.
About General Biomics
General Biomics Inc. is an early stage, privately funded company headquartered in Farmington, Connecticut at the UConn technology Incubator. Its mission is to improve human health through the knowledge of the human microbiome. The company’s key asset is a multi-omic data analysis platform that can elucidate the microbiome’s impact of specific medical conditions.
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center and nearly 3,000 employees in locations across the United States (Maine, Connecticut, California), Japan and China. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.
No comments:
Post a Comment